View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 3, 2017

Mundipharma’s Mundesine receives approval from Japan’s MHLW to treat PTCL

Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral T-Cell Lymphoma (PTCL).

Mundipharma has secured regulatory approval of Mundesine (Forodesine hydrochloride) from Japan’s Ministry of Health, Labour and Welfare (MHLW) to treat relapsed / refractory Peripheral T-Cell Lymphoma (PTCL).

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

BioCryst Pharmaceuticals developed the purine-nucleoside phosphorylase (PNP) inhibitor, Mundesine, under a licence with Albert Einstein College of Medicine and Victoria Link.

The approval follows successful clinical trials of Mundesine.

Mundipharma stated that it is working to ensure that patients in Japan receive access to Mundesine soon. 

BioCryst signed a sub-licensing agreement with Mundipharma in 2006 to develop and commercialise forodesine in the field of oncology. The agreement was amended and restated in 2011.

"Mundipharma stated that it is working to ensure that patients in Japan receive access to Mundesine soon."

Under the agreement, BioCryst is set to receive tiered royalties ranging from the mid- to high-single digit percentages of net sales of Forodesine hydrocloride from Mundipharma.

Forodesine is an orally available, transition-state analog inhibitor of PNP, a purine salvage pathway enzyme required for the proliferation of T-cells and B-cells. 

These cells are an essential part of the body's immune system and when multiplied uncontrollably can cause various forms of cancer. 

By inhibiting PNP, selective suppression of T-cells and B-cells would be produced, inducing apoptosis in both types of cells.

BioCryst designs, optimises and develops small-molecule drugs that block key enzymes involved in rare diseases.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology